Clinical Efficacy of Sildenafil 100mg Hexal

Subgroup analyses showed a large treatment effect in secondary RP (SMD = 0.95; 95% CI, 0.25–1.65; P = .008) and moderate effect in primary RP (SMD = 0.45; 95% CI, 0.05–0.85; P = .03) [65]. A relatively novel therapy that shows promise in RP involves the local injection of botulinum toxin type A (Btx-A) in the hands of patients with SSc. Btx-A is a neurotoxin that acts as a neuromuscular blocking agent by blocking the release of acetylcholine from presynaptic nerve terminals, thereby interfering with vascular smooth muscle contraction and enhancing local circulation [66]. In a recent double-blind, RCT, Btx-A was administered (50 units in 2.5 ml sterile saline) in one randomly selected hand and sterile saline (2.5 ml) in the opposite hand [67]. Follow-up at 1 and 4 months post-injection included laser Doppler imaging of hands, patient-reported outcomes, and physical examination.

Auswirkungen auf die Gesellschaft

At 1-month follow-up, a significantly greater reduction in average blood flow was observed in Btx-A-treated hands compared to placebo-treated hands (p = 0.024). Change in blood flow at a 4-month follow-up was not significantly different between groups. Ultimately, the investigators concluded that there may be a role of Btx-A in treating a subset of patients with RP, and that further studies defining the patients who are most likely to benefit from this intervention are warranted. A phase 3 study is currently recruiting in France to assess whether or not a single injection schedule of BTX-A in both hands improves RP secondary to SSc better than a placebo at 4, 12, and 24 weeks after the treatment. Riociguat, a stimulator of soluble guanylate cyclase which has downstream effects stimulating vasodilation, was recently studied to determine its efficacy and safety in SSc-associated digital ulcers [68]. In this multi-center randomized, double-blind, placebo-controlled pilot study, SSc patients with at least one visible active or painful digital ulcer were enrolled and randomized (1:1 placebo or riociguat maximum of 2.5 mg three times daily) for an 8-week titration period, followed by an 8-week stable dosing period.

An optional 16-week open-label extension phase for patients with active DU/reoccur-rence of DUs within 1 month of the end of the main treatment phase followed. Ultimately, treatment with riociguat did not reduce the number of digital ulcer burden compared to placebo at 16 weeks.

About this chapter

The effects of statins on endothelial dysfunction and RP in SSc are currently under study by a group in Pittsburgh [69]. In this double-blind, randomized, placebo-controlled trial of atorvastatin 40 mg once daily vs placebo, 24 patients with early diffuse SSc (<3 years of SSc symptoms and RP) were enrolled if they had been on stable RP medications for at least 4 weeks.

• The medication may cause a burning sensation or rash.
• It’s not recommended for use in women.
• Sildenafil is sometimes used off-label for pulmonary hypertension.
• Do not share your medication with others.
• Monitor blood pressure regularly during use.

Improvement in microvascular endothelial function measured by reactive hyperemia index (RHI) was the primary outcome, and secondary outcomes included change in macrovascular endothelial function by brachial flow-mediated (FMD) dilation, and RP severity using the RP condition score (RCS) and visual analog scale (RP-VAS). In the atorvastatin treatment group, 60% (6/10) of patients improved their RHI, compared to 29% (4/14) in the placebo group (p = 0.12). No difference in change in peak FMD% was noted between groups. The RCS decreased 2 points in the statin group compared to no change in the placebo (p = 0.12; Table 2). While the results demonstrated a non-significant improvement in microvascular endothelial function and RCS scores with the treatment of atorvastatin, the number of patients enrolled into the trial was small and thus it may have been underpowered to capture a significant difference between groups.

2. Novel strategies for treating complications of SSC

Determining whether the initiation of therapy at this earlier stage of PAH is beneficial for patients is another key focus of ongoing investigation [74]. Data from the Pulmonary sildenafil 100mg blue pill Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry suggest that patients with SSc-related PAH have a significantly shorter time to clinical worsening when treated with phosphodiesterase-5 inhibitor (PDE5i) monotherapy compared to patients treated with endothelin receptor antagonists (ERA) and PDE5i combination therapy [75]. Such data have fueled interest in the study of combination therapy for PAH in SSc. Upfront combination therapy with phosphodiesterase inhibitors and endothelial receptor antagonists was recently studied in the a treatment-naïve group of patients with SSc-PAH. In this multi-center, open-label, clinical trial, patients were treated for 36 weeks with tadalafil 20 mg daily and ambrisentan 5 mg daily, with medication up-titration occurring at week 4 as tolerated.

Download citation

Investigators then compared the change in RV mass on cardiac MRI (standard volumetric cine images) from baseline to 36-week follow-up within subjects. They found that measures of right and left ventricular systolic and diastolic function were improved after treatment. In addition, combination therapy was associated with significant improvements in RV and LV function as measured by cardiac MRI [76], suggesting that combining these medications is a promising therapeutic strategy. Although trials comparing the efficacy of combination therapy vs. monotherapy for pulmonary hypertension in SSc are limited, one study compared the efficacy and safety of monotherapy with phosphodiesterase inhibitors (sildenafil) versus initial combination therapy with phosphodiesterase inhibitors and endothelial receptor antagonists (sildenafil and bosentan) for treatment of SSc-PAH.

Cite this chapter

In this single-center, double-blind, RCT, 34 patients with SSc-PAH (Pulmonary Artery Systolic Pressures >35 mmHg by echocar-diography), with a forced vital capacity >60% were randomized to receive either sildenafil plus placebo or to combination therapy with sildenafil plus bosentan for 24 weeks. Ultimately, there were no significant changes between groups in pulmonary artery pressures at 24 weeks from baseline, or in secondary end points including change in 6 Minute Walk Distance or Time To Clinical Worsening (TTCW is defined as the first occurrence of all-cause deaths, PAH related hospitalization, worsening of symptoms defined as a decrease of >15% in 6 min walk distance and worsening of NYHA functional class); however, the investigators recommended larger, better powered studies, as combination therapy was well-tolerated in these patients [77] (NCT03053739). Because of the interest in treating early PAH, investigators have also explored the role of treating exercise-induced pulmonary hypertension (PH) in SSc. In cardiology, stress tests are increasingly utilized to better characterize hemodynamic changes, and a strong rationale now exists to suggest that a reduction in pulmonary vascular reserve may be an early signal of subclinical pulmonary hypertension [78]. Some studies now suggest that among SSc patients with normal resting mPAP, an excessive increase in mPAP during exercise coupled with an impairment in vascular dispensability may be indicative of an early stage of pulmonary vasculopathy, associated with reduced survival similar to patients with PH measured at rest [79,80]. Although acetylsalicylic acid (ASA) has been available for over 100 years, it has not been systematically studied in SSc, and it may potentially play a role in preventing SSc-related vascular injury. An ongoing study in Brazil aims to evaluate the effectiveness of ASA on microcirculation alterations in SSc patients. In this phase 4 placebo-controlled clinical trial, 70 patients will be randomized to take either 100 mg daily ASA or placebo for 4 weeks. Outcome measures will include periungual panoramic capillary microscopy, videocapillaroscopy and laser Doppler imaging, as well as a panel of vascular biomarkers.

• This medication is available by prescription only.
• Alcohol consumption may decrease its effectiveness.
• Sildenafil 100mg Hexal is not for recreational use.
• Inform your doctor about other medications you're taking.
• It can cause sudden vision loss in rare cases.

This study is still recruiting and results are not yet available. Pulmonary arterial hypertension (PAH) affects approximately 7–12% of patients with SSc, and it is recognized as a leading cause of SSc-related death [70,71].

Mode of Action TOURNES 100mg

A pilot study recently evaluated whether treatment of exercise-induced PH open-label daily ambrisentan positively affects changes in a 24-week interval in hemodynamics and exercise capacity in patients with SSc. Exercise-induced PH was defined as a mean pulmonary artery pressure of >30 mm Hg with maximum exercise and a transpulmonary gradient (TPG) of >15 mm Hg. Patients had normal hemodynamics at rest and were treated with 5–10 mg of ambrisentan daily. From baseline to 24 weeks, significant changes were identified in mean exercise pulmonary vascular resistance, mean 6 minute walk distance, mean exercise cardiac output, mean pulmonary artery pressure, and total pulmonary resistance. Placebo-controlled studies are now needed to confirm that these findings are attributable to a drug effect and to define the optimal therapeutic regimen for these patients [81].

Erektile Dysfunktion (ED)

The application of statin therapy is novel in the management of PAH. Statins have a vasoprotective effect, and may therefore add value to the management of PAH, a condition in which vascular dysfunction is prominent.

2.2. Interstitial lung disease

Right ventricular failure has been associated with poor survival in SSc-PAH, and modest responses to existing therapies leave SSc patients with PAH with a higher relative mortality compared to PAH from other causes [72,73]. Monotherapy with prostacyclins, phosphodiesterase inhibitors, and endothelin receptor antagonists were the standard of care for many years. However, given the significant morbidity and mortality still associated with SSc-PAH, ongoing studies are now exploring alternative strategies, including the novel approach of combining these therapies (Table 5). [74] In addition, because approximately 50–70% of the pulmonary vasculature needs to be affected or obstructed before resting mPAP is elevated, investigators are also now exploring the treatment of exercise pulmonary hypertension (abnormal hemodynamic response to exercise), which is likely a marker of early pulmonary vascular disease.

• Do not drive or operate machinery after taking Sildenafil.
• It may cause temporary vision disturbances.
• Notify your doctor of any heart problems.
• Take the medication with water, not with a heavy meal.
• Keep out of reach of children.

Determining whether the initiation of therapy at this earlier stage of PAH is beneficial for patients is another key focus of ongoing investigation [74]. Data from the Pulmonary sildenafil 100mg blue pill Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry suggest that patients with SSc-related PAH have a significantly shorter time to clinical worsening when treated with phosphodiesterase-5 inhibitor (PDE5i) monotherapy compared to patients treated with endothelin receptor antagonists (ERA) and PDE5i combination therapy [75]. Such data have fueled interest in the study of combination therapy for PAH in SSc. Upfront combination therapy with phosphodiesterase inhibitors and endothelial receptor antagonists was recently studied in the a treatment-naïve group of patients with SSc-PAH. In this multi-center, open-label, clinical trial, patients were treated for 36 weeks with tadalafil 20 mg daily and ambrisentan 5 mg daily, with medication up-titration occurring at week 4 as tolerated. Investigators then compared the change in RV mass on cardiac MRI (standard volumetric cine images) from baseline to 36-week follow-up within subjects.

4. Expert opinion

They found that measures of right and left ventricular systolic and diastolic function were improved after treatment. In addition, combination therapy was associated with significant improvements in RV and LV function as measured by cardiac MRI [76], suggesting that combining these medications is a promising therapeutic strategy. Although trials comparing the efficacy of combination therapy vs.

TOURNES 100mg Interactions TOURNES 100mg

Subgroup analyses showed a large treatment effect in secondary RP (SMD = 0.95; 95% CI, 0.25–1.65; P = .008) and moderate effect in primary RP (SMD = 0.45; 95% CI, 0.05–0.85; P = .03) [65]. A relatively novel therapy that shows promise in RP involves the local injection of botulinum toxin type A (Btx-A) in the hands of patients with SSc. Btx-A is a neurotoxin that acts as a neuromuscular blocking agent by blocking the release of acetylcholine from presynaptic nerve terminals, thereby interfering with vascular smooth muscle contraction and enhancing local circulation [66]. In a recent double-blind, RCT, Btx-A was administered (50 units in 2.5 ml sterile saline) in one randomly selected hand and sterile saline (2.5 ml) in the opposite hand [67]. Follow-up at 1 and 4 months post-injection included laser Doppler imaging of hands, patient-reported outcomes, and physical examination.

Off-Label und potentielle Anwendungsgebiete

At 1-month follow-up, a significantly greater reduction in average blood flow was observed in Btx-A-treated hands compared to placebo-treated hands (p = 0.024). Change in blood flow at a 4-month follow-up was not significantly different between groups. Ultimately, the investigators concluded that there may be a role of Btx-A in treating a subset of patients with RP, and that further studies defining the patients who are most likely to benefit from this intervention are warranted. A phase 3 study is currently recruiting in France to assess whether or not a single injection schedule of BTX-A in both hands improves RP secondary to SSc better than a placebo at 4, 12, and 24 weeks after the treatment. Riociguat, a stimulator of soluble guanylate cyclase which has downstream effects stimulating vasodilation, was recently studied to determine its efficacy and safety in SSc-associated digital ulcers [68].

2.3. Raynaud phenomenon

In this multi-center randomized, double-blind, placebo-controlled pilot study, SSc patients with at least one visible active or painful digital ulcer were enrolled and randomized (1:1 placebo or riociguat maximum of 2.5 mg three times daily) for an 8-week titration period, followed by an 8-week stable dosing period. An optional 16-week open-label extension phase for patients with active DU/reoccur-rence of DUs within 1 month of the end of the main treatment phase followed. Ultimately, treatment with riociguat did not reduce the number of digital ulcer burden compared to placebo at 16 weeks. The effects of statins on endothelial dysfunction and RP in SSc are currently under study by a group in Pittsburgh [69]. In this double-blind, randomized, placebo-controlled trial of atorvastatin 40 mg once daily vs placebo, 24 patients with early diffuse SSc (<3 years of SSc symptoms and RP) were enrolled if they had been on stable RP medications for at least 4 weeks. monotherapy for pulmonary hypertension in SSc are limited, one study compared the efficacy and safety of monotherapy with phosphodiesterase inhibitors (sildenafil) versus initial combination therapy with phosphodiesterase inhibitors and endothelial receptor antagonists (sildenafil and bosentan) for treatment of SSc-PAH. In this single-center, double-blind, RCT, 34 patients with SSc-PAH (Pulmonary Artery Systolic Pressures >35 mmHg by echocar-diography), with a forced vital capacity >60% were randomized to receive either sildenafil plus placebo or to combination therapy with sildenafil plus bosentan for 24 weeks. Ultimately, there were no significant changes between groups in pulmonary artery pressures at 24 weeks from baseline, or in secondary end points including change in 6 Minute Walk Distance or Time To Clinical Worsening (TTCW is defined as the first occurrence of all-cause deaths, PAH related hospitalization, worsening of symptoms defined as a decrease of >15% in 6 min walk distance and worsening of NYHA functional class); however, the investigators recommended larger, better powered studies, as combination therapy was well-tolerated in these patients [77] (NCT03053739). Because of the interest in treating early PAH, investigators have also explored the role of treating exercise-induced pulmonary hypertension (PH) in SSc.

Frequently Asked Questions

Improvement in microvascular endothelial function measured by reactive hyperemia index (RHI) was the primary outcome, and secondary outcomes included change in macrovascular endothelial function by brachial flow-mediated (FMD) dilation, and RP severity using the RP condition score (RCS) and visual analog scale (RP-VAS). In the atorvastatin treatment group, 60% (6/10) of patients improved their RHI, compared to 29% (4/14) in the placebo group (p = 0.12). No difference in change in peak FMD% was noted between groups. The RCS decreased 2 points in the statin group compared to no change in the placebo (p = 0.12; Table 2). While the results demonstrated a non-significant improvement in microvascular endothelial function and RCS scores with the treatment of atorvastatin, the number of patients enrolled into the trial was small and thus it may have been underpowered to capture a significant difference between groups.

Active Substance

Although acetylsalicylic acid (ASA) has been available for over 100 years, it has not been systematically studied in SSc, and it may potentially play a role in preventing SSc-related vascular injury. An ongoing study in Brazil aims to evaluate the effectiveness of ASA on microcirculation alterations in SSc patients. In this phase 4 placebo-controlled clinical trial, 70 patients will be randomized to take either 100 mg daily ASA or placebo for 4 weeks. Outcome measures will include periungual panoramic capillary microscopy, videocapillaroscopy and laser Doppler imaging, as well as a panel of vascular biomarkers. This study is still recruiting and results are not yet available.

2.5. Gastrointestinal disease

Pulmonary arterial hypertension (PAH) affects approximately 7–12% of patients with SSc, and it is recognized as a leading cause of SSc-related death [70,71]. Right ventricular failure has been associated with poor survival in SSc-PAH, and modest responses to existing therapies leave SSc patients with PAH with a higher relative mortality compared to PAH from other causes [72,73]. Monotherapy with prostacyclins, phosphodiesterase inhibitors, and endothelin receptor antagonists were the standard of care for many years. However, given the significant morbidity and mortality still associated with SSc-PAH, ongoing studies are now exploring alternative strategies, including the novel approach of combining these therapies (Table 5). [74] In addition, because approximately 50–70% of the pulmonary vasculature needs to be affected or obstructed before resting mPAP is elevated, investigators are also now exploring the treatment of exercise pulmonary hypertension (abnormal hemodynamic response to exercise), which is likely a marker of early pulmonary vascular disease. In cardiology, stress tests are increasingly utilized to better characterize hemodynamic changes, and a strong rationale now exists to suggest that a reduction in pulmonary vascular reserve may be an early signal of subclinical pulmonary hypertension [78]. Some studies now suggest that among SSc patients with normal resting mPAP, an excessive increase in mPAP during exercise coupled with an impairment in vascular dispensability may be indicative of an early stage of pulmonary vasculopathy, associated with reduced survival similar to patients with PH measured at rest [79,80]. A pilot study recently evaluated whether treatment of exercise-induced PH open-label daily ambrisentan positively affects changes in a 24-week interval in hemodynamics and exercise capacity in patients with SSc.

Exercise-induced PH was defined as a mean pulmonary artery pressure of >30 mm Hg with maximum exercise and a transpulmonary gradient (TPG) of >15 mm Hg. Patients had normal hemodynamics at rest and were treated with 5–10 mg of ambrisentan daily. From baseline to 24 weeks, significant changes were identified in mean exercise pulmonary vascular resistance, mean 6 minute walk distance, mean exercise cardiac output, mean pulmonary artery pressure, and total pulmonary resistance. Placebo-controlled studies are now needed to confirm that these findings are attributable to a drug effect and to define the optimal therapeutic regimen for these patients [81]. The application of statin therapy is novel in the management of PAH. Statins have a vasoprotective effect, and may therefore add value to the management of PAH, a condition in which vascular dysfunction is prominent.